Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of GenSci048 (金纳单抗注射液) in active non-infectious intermediate, posterior, or panuveitis
CTR20261627Phase 2Active
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of genakumab in noninfectious uveitis (NIU), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Jul 2026; status: active.
02
Drugs
genakumab
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on CTR20261627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261627.